Finally, in Aim 3, we will develop and validate predictive tumor, immunological and imaging biomarkers of response in recurrent glioblastoma patients enrolled in a Phase II clinical trial of DCVax-L +/- PD-1 blockade.
I've written on this board several times now that I met LL at a presentation last year in early February (before the Covid shutdown) where I spoke alone to her for at least 5 minutes; and then at the end of the session, spoke with Dr. Ngheimphu alone for maybe 10 minutes, and they both assured me that the vaccine being used in the UCLA combo trial is DCVax-L being made at UCLA at this time.